Related Experiment Video
Updated: Aug 5, 2026
07:05
Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis
Published on: May 17, 2015
Heparin-Binding Protein and Transplant-Associated Inflammation: Emerging Roles in Infection, Ischemia-Reperfusion
Chengchang Zhang1,2,3,4,5,6, Ruozhu Li1,2,3,4,5,6, Chen Dai1,2,3,4,5,6
1Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, China.
Journal of Clinical Medicine
|July 28, 2026
Summary
Heparin-binding protein (HBP) plays a role in transplant complications like infection and rejection. Targeting HBP may offer therapeutic benefits, but further clinical studies are needed to confirm its role as a biomarker and treatment target.
Area of Science:
- Immunology
- Transplantation Biology
- Vascular Inflammation
Background:
- Heparin-binding protein (HBP) is a key mediator of inflammation and tissue injury.
- While studied in sepsis, HBP's role in transplantation is emerging.
- Transplant complications share inflammatory pathways involving neutrophil activation and endothelial injury.
Purpose of the Study:
- To review HBP biology and its potential role in transplant complications.
- To evaluate HBP as a biomarker for infection, inflammation, and graft injury.
- To assess HBP-targeted therapies for transplantation.
Main Methods:
- Literature review of HBP in innate immunity and transplantation.
- Analysis of shared pathological features between HBP activity and transplant complications.
- Critical assessment of existing and emerging HBP-targeted therapeutic strategies.
Main Results:
- HBP is implicated in neutrophil activation, endothelial injury, and inflammatory amplification relevant to transplantation.
- HBP shows potential as an early biomarker for infection surveillance and graft injury.
- Preliminary evidence supports HBP-targeted interventions, but clinical data is limited.
Conclusions:
- HBP is a potential biomarker and therapeutic target in transplantation.
- Further mechanistic and prospective studies are required for clinical validation.
- HBP-targeted therapies require robust clinical trials in transplant recipients.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:25Acute Inflammation III: Local and Systemic Effects
Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...
01:24Tissue Transplantation
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:28Kidney Transplant I: Introduction
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
01:05Introduction to Hemostasis
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...